EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

GWAS Identifies SNPs Associated With Severe Adverse Events and Efficacy in Advanced Renal Cell Carcinoma Treated With Nivolumab

GWAS identifiziert SNPs, die mit schweren unerwünschten Ereignissen und Wirksamkeit bei fortgeschrittenem Nierenzellkarzinom unter Nivolumab assoziiert sind

Tokiyoshi Tanegashima iD, Masaki Shiota iD, Shusuke Akamatsu, Hideaki Miyake, Masayuki Takahashi, Mototsugu Oya iD, Norihiko Tsuchiya, Naoya Masumori, Hideyasu Matsuyama, Wataru Obara iD, Nobuo Shinohara iD, Kiyohide Fujimoto iD und 15 weitere

Cancer Science · 2025-12 · 116 (12) · 3300-3308

DOI: 10.1111/cas.70204 ↗

Auf einen Blick

Eine GWAS bei fortgeschrittenem klarzelligem Nierenzellkarzinom unter Nivolumab identifizierte genetische Marker für schwere therapiebedingte Nebenwirkungen. rs2545737/CHD1 war zudem mit längerem progressionsfreiem Überleben verbunden.

Fragestellung

Welche genetischen Marker sind bei fortgeschrittenem klarzelligem Nierenzellkarzinom unter Nivolumab mit schweren therapiebedingten unerwünschten Ereignissen und dem Behandlungsergebnis assoziiert?

Methode

GWAS in einer Entwicklungskohorte; 13 der 16 SNPs wurden in einer Validierungskohorte genotypisiert. Rekrutierung vom 19. August 2019 bis 30. September 2020 in 23 Zentren in Japan; Follow-up bis 31. März 2021.

Ergebnisse

16 SNPs wurden identifiziert; 13 wurden in der Validierungskohorte genotypisiert. 8 SNPs zeigten konsistente Trends, erreichten dort aber keine statistische Signifikanz. rs2545737/CHD1 war signifikant mit längerem PFS verbunden.

Einschränkungen

Die Befunde aus der Entwicklungskohorte konnten in der Validierungskohorte nicht repliziert werden.

Schlussfolgerung der Autor:innen

Die Ergebnisse konnten in der Validierungskohorte nicht bestätigt werden; weitere Re-Validierung in der RCC-Population ist laut Autor:innen erforderlich.

Kernaussagen

  • 16 SNPs in der Entwicklungskohorte identifiziert
  • 8 SNPs mit konsistentem Trend, aber ohne Signifikanz in der Validierung
  • rs2545737/CHD1 mit längerem PFS assoziiert

Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Science, online erschienen am 24.09.2025. Verfasst von Tokiyoshi Tanegashima und 26 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan. Hauptthemen laut MEDLINE: Nivolumab, Carcinoma, Renal Cell, Polymorphism, Single Nucleotide, Kidney Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Clinical Research Support Center Kyushu from Ono Pharmaceutical and Bristol-Myers Squibb.

Auf einen BlickAbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of advanced renal cell carcinoma (RCC). However, ICIs often induce immune‐related adverse events (irAEs), which vary greatly among individuals and may influence treatment outcomes. This study aimed to identify genetic markers associated with the risk of severe treatment‐related adverse events (trAEs) and assess their impact on patient prognosis. From August 19, 2019, to September 30, 2020, patient recruitment for nivolumab treatment in advanced clear cell RCC (ccRCC) was conducted across 23 institutions in Japan, with follow‐up concluding on March 31, 2021 (protocol ID: UMIN000037739). A genome‐wide association study (GWAS) was conducted in a development cohort to identify single nucleotide polymorphisms (SNPs) associated with severe trAEs following nivolumab. Sixteen SNPs were identified, and thirteen were genotyped in a validation cohort. Eight SNPs showed consistent trends with the development cohort, but they have not reached statistical significance in the validation cohort. Among them, rs2545737, corresponding to CHD1 , was significantly linked to prolonged progression‐free survival (PFS), highlighting its potential as a biomarker for both safety and efficacy. Further analysis indicated that high CHD1 expression in tumors correlated with improved overall survival in nivolumab‐treated patients but not in those receiving everolimus. Given the failure to replicate the development set findings in our validation cohort, further re‐validation within the RCC population is warranted. However, these results enhance our understanding of the genetic predisposition to trAEs and provide a significant step toward safer and more effective cancer treatment strategies. This study was registered on the University Hospital Medical Information Network (UMIN) in Japan on August 20, 2019 (protocol ID: UMIN000037739).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NivolumabCarcinoma, Renal CellPolymorphism, Single NucleotideKidney NeoplasmsImmune Checkpoint InhibitorsHumansMaleGenome-Wide Association StudyFemaleAgedMiddle AgedPrognosisProgression-Free SurvivalBiomarkers, TumorJapanAged, 80 and overAdult

Stichwörter der Autor:innen

anti‐PD‐1 antibodygenome‐wide association studynivolumabrenal cell carcinomasingle nucleotide polymorphismtreatment‐related adverse event

Substanzen

NivolumabImmune Checkpoint InhibitorsBiomarkers, Tumor

Autor:innen und Institutionen

  • Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
  • Department of Urology, Kyoto University Graduate School of Medicine, Kyoto, Japan.
  • Department of Urology, Hamamatsu University School of Medicine, Hamamatsu, Japan.
  • Department of Urology, Tokushima University Graduate School of Biomedical Sciences, Tokushima, Japan.
  • Department of Urology, Keio University School of Medicine, Tokyo, Japan.
  • Department of Urology, Faculty of Medicine, Yamagata University, Yamagata, Japan.

ORCID-Profile: Tokiyoshi Tanegashima, Masaki Shiota, Mototsugu Oya, Wataru Obara, Nobuo Shinohara, Kiyohide Fujimoto, Keiichi Ito, Masatoshi Eto

Förderung

  • Clinical Research Support Center Kyushu from Ono Pharmaceutical and Bristol-Myers Squibb

Zitieren

APA

Tanegashima, T., Shiota, M., Akamatsu, S., Miyake, H., Takahashi, M., Oya, M., Tsuchiya, N., Masumori, N., Matsuyama, H., Obara, W., Shinohara, N., Fujimoto, K., Nozawa, M., Ohba, K., Ohyama, C., Hashine, K., Kamba, T., Mita, K., Gotoh, M., …, & SNiP‐RCC investigators (2025). GWAS Identifies SNPs Associated With Severe Adverse Events and Efficacy in Advanced Renal Cell Carcinoma Treated With Nivolumab. Cancer Science, 116(12), 3300-3308. https://doi.org/10.1111/cas.70204

Vancouver

Tanegashima T, Shiota M, Akamatsu S, Miyake H, Takahashi M, Oya M, et al. GWAS Identifies SNPs Associated With Severe Adverse Events and Efficacy in Advanced Renal Cell Carcinoma Treated With Nivolumab. Cancer Science. 2025;116(12):3300-3308. doi:10.1111/cas.70204

BibTeX
@article{Tanegashima2025,
  author = {Tanegashima, Tokiyoshi and Shiota, Masaki and Akamatsu, Shusuke and Miyake, Hideaki and Takahashi, Masayuki and Oya, Mototsugu and Tsuchiya, Norihiko and Masumori, Naoya and Matsuyama, Hideyasu and Obara, Wataru and Shinohara, Nobuo and Fujimoto, Kiyohide and Nozawa, Masahiro and Ohba, Kojiro and Ohyama, Chikara and Hashine, Katsuyoshi and Kamba, Tomomi and Mita, Koji and Gotoh, Momokazu and Tatarano, Shuichi and Fujisawa, Masato and Tomita, Yoshihiko and Mukai, Shoichiro and Ito, Keiichi and Tokunaga, Shoji and Eto, Masatoshi and SNiP‐RCC investigators, SNiP‐RCC investigators},
  title = {GWAS Identifies SNPs Associated With Severe Adverse Events and Efficacy in Advanced Renal Cell Carcinoma Treated With Nivolumab},
  journal = {Cancer Science},
  year = {2025},
  volume = {116},
  number = {12},
  pages = {3300--3308},
  doi = {10.1111/cas.70204}
}
Kostenlos starten →